Terapia Génica del Cáncer
TGC
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (6)
2023
-
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Nature Communications, Vol. 14, Núm. 1
2022
-
Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447] (ESMO Open (2022) 7(2), (S2059702922000631), (10.1016/j.esmoop.2022.100447))
ESMO Open
-
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
ESMO Open, Vol. 7, Núm. 2
-
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery
BJS Open, Vol. 6, Núm. 1
2021
-
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 779-789
2020
-
Atypical patterns of response and progression in the era of immunotherapy combinations
Future Oncology, Vol. 16, Núm. 23, pp. 1707-1713